Industries > Pharma > Global Cholesterol-Lowering Drugs Market 2017-2027

Global Cholesterol-Lowering Drugs Market 2017-2027

Statins and Fixed-Dose Combinations, Cholesterol Absorption Inhibitors, Ion Exchange Resins, Fibrates, PCSK9 Inhibitors, Novel Drugs

PUBLISHED: 25 August 2017
PAGES: 181
PRODUCT CODE: PHA0229
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA0229 Categories: ,

The global cholesterol-lowering drugs market is expected to grow at a CAGR of 4.9% in the first half of the forecast period. The market is estimated at $19.2bn in 2017. In the Statins and Fixed-Dose Combinations segment, Crestor was on the lead in 2016 and held a share of 26.7%.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 181-page report you will receive 89 tables and 107 figures – all unavailable elsewhere.

The 181-page report provides clear detailed insight into the global cholesterol-lowering drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

Global Cholesterol-Lowering Drugs market forecasts from 2017-2027

• This report also breaks down the revenue forecast from 2017-2027 for the global cholesterol-lowering drugs market by its main segments:
• Statins and Fixed-Dose Combinations
• Cholesterol Absorption Inhibitors, Ion Exchange Resins, Fibrates
• PCSK9 Inhibitors
• Novel Cholesterol-Lowering Drugs

• This report provides revenue forecast from 2017-2027 for the leading drugs under the Statins and Fixed-Dose Combination segment:
• Crestor
• Lipitor
• Livalo
• Lescol/Lescol XL
• Zocor
• Vytorin
• Caduet
• Others

• This report provides revenue forecast from 2017-2027 for the leading drugs under the Cholesterol Absorption Inhibitors, Ion Exchange Resins, Fibrates segment:
• Zetia
• Welchol
• Tricor
• Others

• This report provides revenue forecast from 2017-2027 for the leading drugs under the PCSK9 Inhibitor segment:
• Praluent
• Repatha
• RN316
• Others

• This report provides revenue forecast from 2017-2027 for the leading drugs under the novel cholesterol-lowering drugs segment:
• Juxtapid
• Kynamro
• MK-0859
• Others

• This report provides individual revenue forecasts to 2027 for these regional and national markets:
• North America: the US, Canada, Mexico
• South America: Brazil, Argentina, Paraguay, Bolivia, Rest of South America
• Europe: Germany, France, the UK, Spain, Italy, Rest of Europe
• Asia-Pacific: Japan, China, India, Australia, Thailand, Rest of APAC
• RoW: Middle East, Africa, Other Countries

Global Cholesterol-Lowering Drugs Market 2017-2027

• Our study provides SWOT and Porter’s Five Forces analysis that influence the global cholesterol-lowering drugs market

• Our study discusses the selected leading companies that are the major players in the cholesterol-lowering drugs market:
• AstraZeneca
• Merck & Co
• Pfizer
• Kowa Company
• Daiichi Sankyo
• AbbVie
• Novartis
• Sanofi
• Amgen
• Bristol-Myers Squibb (BMS)
 
Visiongain’s study is intended for anyone requiring commercial analyses for the global cholesterol-lowering drugs market. You find data, trends and predictions.

Buy our report today Global Cholesterol-Lowering Drugs Market 2017-2027: Statins and Fixed-Dose Combinations, Cholesterol Absorption Inhibitors, Ion Exchange Resins, Fibrates, PCSK9 Inhibitors, Novel Drugs.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Cholesterol-Lowering Drugs Market 2017-2027


Download sample pages

Complete the form below to download your free sample pages for Global Cholesterol-Lowering Drugs Market 2017-2027


Latest Pharma news

Visiongain Publishes Clinical Trial Supplies Market Report 2021-2031

Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.

11 October 2021

READ

Visiongain Publishes Drug Discovery Informatics Market Report 2021-2031

High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.

07 October 2021

READ

Visiongain Publishes Pharma Wholesale and Distribution Market Report 2021-2031

Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.

06 October 2021

READ

Visiongain Publishes Meningococcal Vaccines Market Report 2021-2031

Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market

05 October 2021

READ

Categories